Virginia Retirement Systems ET AL continued to hold its stake in Opko Health, Inc. (NASDAQ:OPK) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,100 shares of the biotechnology company’s stock at the end of the second quarter. Virginia Retirement Systems ET AL’s holdings in Opko Health were worth $323,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Credit Suisse AG raised its stake in Opko Health by 122.0% during the first quarter. Credit Suisse AG now owns 746,958 shares of the biotechnology company’s stock worth $5,976,000 after buying an additional 410,445 shares during the last quarter. State Street Corp raised its stake in Opko Health by 40.3% during the first quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock worth $87,412,000 after buying an additional 3,138,685 shares during the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD raised its stake in Opko Health by 14.8% during the second quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD now owns 135,401 shares of the biotechnology company’s stock worth $910,000 after buying an additional 17,458 shares during the last quarter. Skandinaviska Enskilda Banken AB publ bought a new position in Opko Health during the first quarter worth $4,450,000. Finally, Paloma Partners Management Co raised its stake in Opko Health by 70.1% during the first quarter. Paloma Partners Management Co now owns 160,970 shares of the biotechnology company’s stock worth $1,288,000 after buying an additional 66,327 shares during the last quarter. 22.46% of the stock is owned by institutional investors and hedge funds.
In related news, CEO Phillip Md Et Al Frost acquired 200,000 shares of the firm’s stock in a transaction on Thursday, June 15th. The stock was acquired at an average cost of $6.43 per share, for a total transaction of $1,286,000.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $19,733,354.93. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have acquired a total of 1,048,500 shares of company stock valued at $6,660,438 in the last three months. 40.19% of the stock is currently owned by corporate insiders.
A number of equities analysts recently weighed in on OPK shares. BidaskClub raised shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $19.50 target price on shares of Opko Health in a research note on Friday, June 16th. Zacks Investment Research downgraded shares of Opko Health from a “buy” rating to a “hold” rating in a research note on Saturday, August 12th. Jefferies Group LLC reissued a “hold” rating and set a $6.50 target price (down previously from $6.80) on shares of Opko Health in a research note on Thursday, August 10th. Finally, Barrington Research lifted their target price on shares of Opko Health to $11.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $15.28.
TRADEMARK VIOLATION WARNING: This story was published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/09/11/virginia-retirement-systems-et-al-has-323000-position-in-opko-health-inc-opk.html.
Shares of Opko Health, Inc. (OPK) opened at 6.13 on Monday. The firm has a 50-day moving average of $6.24 and a 200 day moving average of $6.97. The company’s market capitalization is $3.43 billion. Opko Health, Inc. has a 1-year low of $5.85 and a 1-year high of $12.15.
Opko Health (NASDAQ:OPK) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The business had revenue of $314.20 million during the quarter, compared to analysts’ expectations of $322.64 million. Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The firm’s revenue for the quarter was down 12.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.02 EPS. On average, equities research analysts expect that Opko Health, Inc. will post ($0.20) earnings per share for the current year.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health, Inc. (NASDAQ:OPK).
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.